Lifecore Biomedical (Lifecore Biomedical) EV-to-EBIT

Lifecore Biomedical Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	May23
EV-to-EBIT							49.63	-20.48	-27.13	-83.64	-7.24

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
EV-to-EBIT																-83.64	-57.30	-20.04	-10.89	-7.24

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's EV-to-EBIT falls into.

Lifecore Biomedical EV-to-EBIT Calculation

Lifecore Biomedical's EV-to-EBIT for today is calculated as:

Lifecore Biomedical's current Enterprise Value is $286.3 Mil.
Lifecore Biomedical's EBIT for the trailing twelve months (TTM) ended in May. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical  (NAS:LFCR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lifecore Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2023 is calculated as:

Lifecore Biomedical's Enterprise Value for the quarter that ended in May. 2023 was $335.2 Mil.
Lifecore Biomedical's EBIT for the trailing twelve months (TTM) ended in May. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description